ERBB2 and breast carcinoma: Some studies in HER‐2 shedding cell lines have implicated ADAM10 being a major source of HER‐2 sheddase activity.19 Therefore, we tested tissue ADAM10 expression in breast cancer patients with HER‐2 IHC 3+.